{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T14:46:42Z","timestamp":1790952402290,"version":"4.1.0"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Patients with ERBB2 (formerly HER2 or HER2\/neu)-positive metastatic breast cancer (MBC) receiving trastuzumab deruxtecan (T-DXd), a new standard of care, may experience specific adverse events affecting their quality of life (QOL). Monitoring electronic patient-reported outcomes alongside vital signs may help improve their QOL through early detection and management of these symptoms.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess whether symptom tracking and vital sign monitoring improve QOL compared with usual care in patients receiving T-DXd.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This multicenter randomized clinical trial conducted at 38 Japanese hospitals from March 1, 2021, to December 31, 2024, assigned patients with ERBB2-positive MBC eligible for T-DXd to either a monitoring or usual care group.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Randomization was 1:1 for the monitoring and usual care groups. Patients in the monitoring group recorded weekly symptom reports and daily body temperature and percutaneous oxygen saturation data using a smartphone or tablet. Alerts were sent to medical staff when symptom or vital sign thresholds were exceeded.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was the change from baseline in global health status scores at week 24, assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (scores range from 0 to 100, in which higher scores indicate a better quality of life and level of functioning). For symptom scales, however, higher scores indicate a worse symptom burden. Secondary outcomes included changes in functional and symptom scales, as well as survival outcomes.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of 111 female patients enrolled (mean [SD] age, 57.1 [11.0] years), 56 (50.5%) were randomized to the monitoring group and 55 (49.5%) to the usual care group. Baseline patient characteristics and QOL scores were comparable between the 2 groups. At week 24, the mean change in the global health status score from baseline was higher in the monitoring group compared with the usual care group (mean difference, 8.0 [90% CI, 0.2-15.8];\n P<\/jats:italic>\n \u2009=\u2009.09). Improvements in functional scales were noted in the monitoring group for role (mean difference, 10.0 [95% CI, 1.1-18.9]), cognitive (6.3 [95% CI, 1.1-11.5]), and social (10.9 [95% CI, 3.9-18.0]) functioning. Fatigue scores were lower in the monitoring group (mean difference, \u22128.4 [95% CI, \u221216.1 to \u22120.6]), although nausea or vomiting scores were similar between the groups (mean difference, 0.5 [95% CI, \u22126.2 to 7.1]). No significant differences were observed in survival outcomes.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial of patients with ERBB2-positive MBC receiving T-DXd, the findings suggest that electronic symptom and vital sign tracking may help maintain QOL or prevented its deterioration. While survival outcomes were unaffected, this monitoring strategy has potential to enhance patient-centered care.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n jRCT identifier:\n jRCTs031200387<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.27403","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T15:30:36Z","timestamp":1755271836000},"page":"e2527403","source":"Crossref","is-referenced-by-count":10,"title":["Electronic Patient-Reported Outcomes With Vital Sign Monitoring During Trastuzumab Deruxtecan Therapy"],"prefix":"10.1001","volume":"8","author":[{"given":"Yuichiro","family":"Kikawa","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Kansai Medical University, Hirakata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Uemura","sequence":"additional","affiliation":[{"name":"Center for Clinical Science, National Center for Global Health and Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiko","family":"Taira","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Sagara Hospital, Kagoshima, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiyoe","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Hospital Organization Nagoya Medical Center, Nagoya, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Chest Surgery, Teine Keijinkai Hospital, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Aomori Prefectural Central Hospital, Aomori, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuchika","family":"Hosoda","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Hokkaido University Hospital, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Hamanaka","sequence":"additional","affiliation":[{"name":"Department of Breast and Endocrine Surgical Oncology, Graduate School of Medicine, Tohoku University, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Saiseikai Yokohamashi Nanbu Hospital, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Tane","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Hyogo Cancer Center, Akashi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Takabatake","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Breast Surgical Oncology, Tokyo Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Breast and Thyroid Surgery, Kawasaki Medical School Hospital, Kurashiki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Takiguchi","sequence":"additional","affiliation":[{"name":"Medical Affairs Division, Daiichi Sankyo Co, Ltd, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Mukai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruto","family":"Taira","sequence":"additional","affiliation":[{"name":"Breast and Thyroid Surgery, Kawasaki Medical School Hospital, Kurashiki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Sangai","sequence":"additional","affiliation":[{"name":"Department of Breast and Thyroid Surgery, Kitasato University School of Medicine, Sagamihara, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"issue":"1","key":"zoi250771r1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1093\/annonc\/mdx757","article-title":"European Society for Medical Oncology (ESMO) position paper on supportive and palliative care.","volume":"29","author":"Jordan","year":"2018","journal-title":"Ann Oncol"},{"issue":"8","key":"zoi250771r2","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/pon.6183","article-title":"Improving quality of life and symptom experience in patients with metastatic breast cancer: a systematic review of supportive care interventions.","volume":"32","author":"Keane","year":"2023","journal-title":"Psychooncology"},{"issue":"7","key":"zoi250771r3","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer.","volume":"382","author":"Modi","year":"2020","journal-title":"N Engl J Med"},{"issue":"10390","key":"zoi250771r4","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(23)00725-0","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.","volume":"401","author":"Andr\u00e9","year":"2023","journal-title":"Lancet"},{"issue":"12","key":"zoi250771r5","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer.","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi250771r6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer.","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi250771r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies.","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"issue":"4","key":"zoi250771r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100553","article-title":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.","volume":"7","author":"Rugo","year":"2022","journal-title":"ESMO Open"},{"issue":"4","key":"zoi250771r9","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1038\/s41591-025-03507-y","article-title":"Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial.","volume":"31","author":"Basch","year":"2025","journal-title":"Nat Med"},{"issue":"6","key":"zoi250771r10","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial.","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi250771r11","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1200\/JCO.20.02015","article-title":"Phase III randomized controlled trial of eRAPID: eHealth intervention during chemotherapy.","volume":"39","author":"Absolom","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"zoi250771r12","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1093\/jnci\/djad159","article-title":"Quality of life after patient-initiated vs physician-initiated response to symptom monitoring: the SYMPRO-Lung trial.","volume":"115","author":"Billingy","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"zoi250771r13","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.annonc.2023.05.003","article-title":"Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.","volume":"34","author":"Harbeck","year":"2023","journal-title":"Ann Oncol"},{"issue":"3","key":"zoi250771r14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.4427","article-title":"Efficiency of electronic health record assessment of patient-reported outcomes after cancer immunotherapy: a randomized clinical trial.","volume":"5","author":"Zhang","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"zoi250771r15","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jama.2017.7156","article-title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment.","volume":"318","author":"Basch","year":"2017","journal-title":"JAMA"},{"issue":"9","key":"zoi250771r16","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx029","article-title":"Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients.","volume":"109","author":"Denis","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"20","key":"zoi250771r17","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"zoi250771r18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s12282-023-01537-3","article-title":"Pilot trial of an electronic patient-reported outcome monitoring system in patients with metastatic breast cancer undergoing chemotherapy.","volume":"31","author":"Taira","year":"2024","journal-title":"Breast Cancer"},{"issue":"5","key":"zoi250771r19","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw273","article-title":"International psychometric validation of an EORTC quality of life module measuring cancer related fatigue (EORTC QLQ-FA12).","volume":"109","author":"Weis","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"zoi250771r20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10549-015-3633-7","article-title":"Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.","volume":"154","author":"Cortes","year":"2015","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"zoi250771r21","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/annonc\/mdw139","article-title":"Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial.","volume":"27","author":"Harbeck","year":"2016","journal-title":"Ann Oncol"},{"issue":"3","key":"zoi250771r22","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz037","article-title":"Minimally important differences for interpreting EORTC QLQ-C30 scores in patients with advanced breast cancer.","volume":"3","author":"Musoro","year":"2019","journal-title":"J Natl Cancer Inst Cancer Spectr"},{"issue":"1","key":"zoi250771r23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1200\/JCO.2010.28.0107","article-title":"Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30.","volume":"29","author":"Cocks","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi250771r24","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2202\/1557-4679.1098","article-title":"Sample size estimation for repeated measures analysis in randomized clinical trials with missing data.","volume":"4","author":"Lu","year":"2008","journal-title":"Int J Biostat"},{"issue":"24","key":"zoi250771r25","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1001\/jama.2022.9265","article-title":"Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer: a randomized clinical trial.","volume":"327","author":"Basch","year":"2022","journal-title":"JAMA"},{"issue":"9","key":"zoi250771r26","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.annonc.2022.04.007","article-title":"The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline.","volume":"33","author":"Di Maio","year":"2022","journal-title":"Ann Oncol"},{"issue":"4","key":"zoi250771r27","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/01.NURSE.0000553277.03472.d8","article-title":"Healthcare coverage in the US and Japan: a comparison.","volume":"49","author":"Ruggles","year":"2019","journal-title":"Nursing"},{"issue":"4","key":"zoi250771r28","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1200\/JCO.2004.06.078","article-title":"Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial.","volume":"22","author":"Velikova","year":"2004","journal-title":"J Clin Oncol"},{"issue":"10","key":"zoi250771r29","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1136\/bjsports-2016-096422","article-title":"Exercise and other non-pharmaceutical interventions for cancer-related fatigue in patients during or after cancer treatment: a systematic review incorporating an indirect-comparisons meta-analysis.","volume":"52","author":"Hilfiker","year":"2018","journal-title":"Br J Sports Med"},{"issue":"6","key":"zoi250771r30","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1037\/0278-6133.26.6.660","article-title":"Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue.","volume":"26","author":"Jacobsen","year":"2007","journal-title":"Health Psychol"},{"issue":"6","key":"zoi250771r31","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1111\/ecc.12381","article-title":"Non-pharmacological interventions to manage fatigue and psychological stress in children and adolescents with cancer: an integrative review.","volume":"25","author":"Lopes-J\u00fanior","year":"2016","journal-title":"Eur J Cancer Care (Engl)"},{"issue":"5","key":"zoi250771r32","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/jjco\/hyaf033","article-title":"Multicenter, open-label, randomized, controlled study to test the utility of electronic patient-reported outcome monitoring in patients with unresectable advanced cancers or metastatic\/recurrent solid tumors.","volume":"55","author":"Taira","year":"2025","journal-title":"Jpn J Clin Oncol"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2837627\/kikawa_2025_oi_250771_1754585371.89065.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T15:30:37Z","timestamp":1755271837000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2837627"}},"subtitle":["The PRO-DUCE Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.27403","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]}}}